PolyPid Stock

PolyPid Capital Expenditures

The Capital Expenditures (CapEx) of PolyPid (PYPD) as of Aug 7, 2026 is -210,000.00 USD. In the previous year, Capital Expenditures (CapEx) was -76,000.00 USD — a change of 176.32% (lower).

Capital Expenditures

-210,000.00USD

YoY

176.32%

Last updated:

Capital Expenditures (CapEx) of PolyPid is 2026 -210,000.00 USD. Capital Expenditures (CapEx) of PolyPid was 2025 -76,000.00 USD. It decreases by 176.32% lower compared to the previous year.
Access this data via the Eulerpool API

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolyPid stock

Capital Expenditures (CapEx) of PolyPid is -210,000.00 USD in 2026.

Capital Expenditures (CapEx) of PolyPid changed from -76,000.00 USD to -210,000.00 USD, representing a 176.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) PolyPid since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s PolyPid historically and in real time.

Access this data via the Eulerpool API

Cash Flow — PolyPid

All Key Metrics — PolyPid